Andriy Mushak was named Chief Financial Officer of Telomir Pharmaceuticals, Inc., effective June 6, 2026. As of November 6, 2026, Telomir Pharmaceuticals, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on June 8, 2026, naming 1 appointment (Form 8-K, June 8, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Telomir Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Telomir Pharmaceuticals, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-06-08. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Telomir Pharmaceuticals, Inc. files it.
Also on the record for Telomir Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity | 5.169% of the class | 5%+ stakes | Source |
| April 22, 2026 | Acquired TELI Pharmaceuticals, Inc. | — | Acquisition | Source |
| February 12, 2026 | Stake report, Schedule 13G/A, by John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity | 9.438% of the class | 5%+ stakes | Source |
| September 18, 2025 | Stake report, Schedule 13G, by John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity | 5.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Telomir Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Telomir Pharmaceuticals, Inc. and the records around it.
Telomir Pharmaceuticals, Inc. elsewhere on the record
- Acquisition Apr 2026
- Who owns it
Companies that share a holder
- John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity also filed stake reports on 1 other company: HighPeak Energy, Inc. (Sep 2025)
Watch Telomir Pharmaceuticals, Inc.
Get an email when Telomir Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Telomir Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Telomir Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Telomir Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-08 | In | Chief Financial Officer | 2026-06-06 | 8-K, 2026-06-08 |
Who leads Telomir Pharmaceuticals, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Andriy Mushak, appointed, effective 2026-06-06 (filed 2026-06-08).
New leaders reset buying decisions — get the Full Report on Telomir Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Telomir Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Telomir Pharmaceuticals, Inc.Every change, in the filing's words
Appointed: Andriy Mushak, Chief Financial Officer, effective 2026-06-06
On June 3, 2026, the board of directors of the Company appointed Andriy Mushak to serve as the Company's fractional Chief Financial Officer, effective as of June 6, 2026 (the "Effective Date").
- Appointment of Andriy Mushak as the Fractional Chief Financial Officer Effective June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Telomir Pharmaceuticals, Inc. (the "Company").
- Mr. Weichselbaum's departure was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.
- Mr. Mushak, CPA, 43, is an accomplished Certified Public Accountant licensed in the Commonwealth of Massachusetts with over 20 years of experience in SEC reporting, accounting compliance, and financial statement audits.
- Mr. Mushak currently serves as a Partner at LMAM Consulting Group, LLC ("LMAM"), a professional services firm with offices in Dallas, Texas and Boston, Massachusetts, specializing in SEC financial reporting, technical accounting, and M&A transaction support.
- At LMAM, Mr. Mushak leads SEC reporting engagements, financial statement preparation, and advisory services for both publicly traded and privately held companies across diverse industries, including technology, life sciences, media, medical supplies, finance, and manufacturing.
Tools for this story
Each opens in a new tab, filled in for Telomir Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.